Sugi Predict
/ Targets
/ TTBK2
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to TTBK2 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Lithium for Prevention of Cognitive Declining in Mood Illnesses |
PHASE4 | NOT_YET_RECRUITING |
| Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) |
PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING |
| Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer |
PHASE3 | COMPLETED |
| The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus |
PHASE3 | UNKNOWN |
| Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer |
PHASE3 | SUSPENDED |
| A Multicenter Study of NAP (AL-108) in Schizophrenia |
PHASE2 | COMPLETED |
| Vit D and Peripheral Neuropathy in Taxane Naive Patients |
PHASE2 | UNKNOWN |
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors |
PHASE2 | RECRUITING |
| Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer |
PHASE2 | UNKNOWN |
| SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer |
PHASE2 | COMPLETED |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| Study of ABT-751 in Patients With Refractory Hematologic Malignancies |
PHASE1 | COMPLETED |
| A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. |
PHASE1 | COMPLETED |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 |
EARLY_PHASE1 | COMPLETED |
| Generating Intervals of Reference FFor Early Life Brain Biomarkers. |
nan | RECRUITING |
| Evaluation of a Novel PET Radioligand to Image OGA |
nan | COMPLETED |
| NTRK 1,2,3 Rearrangements in Patients With Solid Tumors |
nan | ACTIVE_NOT_RECRUITING |
| A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib |
nan | COMPLETED |
| Prodromal Model of Parkinson's Disease Confined to The Peripheral Nervous System |
nan | ENROLLING_BY_INVITATION |
| The Relation of Microtubule-Associated Protein 2 and Cell Migration |
nan | UNKNOWN |
| Importance of the Microtubule Cytoskeleton in Oocyte Competence |
nan | COMPLETED |
| Rostock International Parkinson's Disease Study (ROPAD) |
nan | COMPLETED |
| LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers |
nan | COMPLETED |
| Natural History Characterization in Symptomatic and Asymptomatic Progranuline Gene Mutation Carriers |
nan | COMPLETED |
| Human CNS Tau Kinetics in Tauopathies |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a TTBK2 binder may also engage these)